Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Cellectar Biosciences, Inc. logo — Learn more about pediatric and AYA clinical trial for HGG at...

Cellectar Biosciences, Inc.

Learn more about pediatric and AYA clinical trial for HGG at www.pediatrichggtrial.com.

Founded 2002 United States United States 20 employees Post Ipo Equity Total: $148.51M Biotechnology, Health and Wellness +1

General Information

Company Name Cellectar Biosciences, Inc.
Founded Year 2002
Location United States United States
Employees 20
Industries Biotechnology, Health and Wellness, Medical Devices
Funding Stage Post Ipo Equity
Social

Get notified when Cellectar Biosciences, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a biotechnology company founded in 2002 and headquartered in the United States. The company is focused on the discovery and development of drugs for the treatment of cancer. Cellectar Biosciences is currently attracting significant attention in the investment landscape, having secured a substantial $103.00M investment in Post-IPO Equity at 05 September 2023 from a consortium of notable investors including Nantahala Capital, Second Line, AuGC Partners, Rosalind Advisors, ADAR1 Partners, and AIGH Capital Management. The company's primary objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop targeted cancer treatments with improved efficacy and safety profiles. Its product pipeline includes CLR 131, a small-molecule PDC designed for targeted delivery of iodine-131, and proprietary preclinical PDC chemotherapeutic programs, as well as multiple partnered PDC assets. Cellectar Biosciences is currently enrolling in a global, pivotal Phase 2 Part B (CLOVER-WaM) expansion study in Waldenstrom’s macroglobulinemia (WM) patients. This study aims to evaluate the efficacy and safety of CLR 131 for marketing approval in a select group of patients. Interested parties can find further information on the company's official website and join the conversation on its social media channels including Twitter, LinkedIn, Facebook, and YouTube. In conclusion, Cellectar Biosciences' innovative approach to cancer treatment, backed by significant investment and ongoing pivotal clinical studies, positions the company as a compelling prospect for venture capital investment.

Taxonomy: Phospholipid Drug Conjugate, Cancer treatment, Drug development, Radioisotope therapy, Clinical trials, Waldenstrom's Macroglobulinemia, CLR 131, Radiopharmaceuticals, Therapeutic drug development, Oncologic payloads, Hematologic malignancies, Madison, Wisconsin, Cellectar Biosciences, Biopharmaceuticals, Targeted therapy

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 5
Investor
•••• •••• 		05 Sep 2023
Grant •••••• 1 •••• •••• 22 Sep 2022
Grant •••••• 1 •••• •••• 18 Aug 2021
Post-IPO Equity •••••• - 16 May 2019
Post-IPO Equity •••••• - 12 Oct 2017

View All 12 Funding Rounds

Cellectar Biosciences, Inc. Alternatives & Competitors

Cellectar Biosciences, Inc. vs
PDC Therapeutics
PDC Therapeutics Switzerland

Biotechnology start-up developing targeted Polymer-Drug Conjugate platform technologies, named Sagit...

4 employees
Biotechnology
Cellectar Biosciences, Inc. vs
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc. Canada

HARNESSING NATURE TO BEAT CANCER

5 employees
Biotechnology, Pharmaceutical
Cellectar Biosciences, Inc. vs
PDC*line Pharma
PDC*line Pharma Belgium

A novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic...

Series B
9 employees
Biotechnology, Health Care

FAQ About Cellectar Biosciences, Inc.

Learn more about pediatric and AYA clinical trial for HGG at www.pediatrichggtrial.com.
Cellectar Biosciences, Inc. was founded in 2002.
Cellectar Biosciences, Inc. is headquartered in United States.
Cellectar Biosciences, Inc. operates in the following industries: Biotechnology, Health and Wellness, Medical Devices.
Cellectar Biosciences, Inc. has approximately 20 employees.
Cellectar Biosciences, Inc. has completed 12 funding rounds, raising a total of $148.51M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Cellectar Biosciences, Inc. include PDC Therapeutics, Alpha Cancer Technologies Inc., PDC*line Pharma, Royer Biomedical Inc, Cybrexa Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cellectar Biosciences, Inc. and PDC Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Cellectar Biosciences, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy